BRIEF-Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Reuters

15 Jan

Jan 15 (Reuters) - Zai Lab Ltd :

* ZAI LAB ANNOUNCES POSITIVE TOPLINE RESULTS FOR TIVDAK IN THE CHINA SUBPOPULATION OF THE GLOBAL PHASE 3 INNOVATV 301 TRIAL IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER

* ZAI LAB LTD - TO SUBMIT NDA FOR TIVDAK TO NMPA IN Q1 2025

* ZAI LAB LTD - TIVDAK IMPROVES OS, PFS, AND ORR IN CHINA SUBPOPULATION

* ZAI LAB LTD - TIVDAK SHOWS 45% REDUCTION IN RISK OF DEATH IN CHINA

* ZAI LAB LTD: SAFETY PROFILE OF TIVDAK AMONG CHINA SUBPOPULATION WAS MANAGEABLE AND CONSISTENT WITH THAT OBSERVED IN GLOBAL POPULATIO

* ZAI LAB LTD - MEDIAN OS FOR TIVDAK NOT REACHED VERSUS CHEMOTHERAPY 10.7 MONTHS

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503431786"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503431786\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503431786?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-15 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503431786","market":"sh","top_or_hot":-1,"title":"BRIEF-Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer","media":"Reuters","content":"<html><body><p>Jan 15 (Reuters) - Zai Lab Ltd   :</p><p>   * ZAI LAB ANNOUNCES POSITIVE TOPLINE RESULTS FOR TIVDAK IN THE CHINA SUBPOPULATION OF THE GLOBAL PHASE 3 INNOVATV 301 TRIAL IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER</p><p>   * ZAI LAB LTD - TO SUBMIT NDA FOR TIVDAK TO NMPA IN Q1 2025</p><p>   * ZAI LAB LTD - TIVDAK IMPROVES OS, PFS, AND ORR IN CHINA SUBPOPULATION</p><p>   * ZAI LAB LTD - TIVDAK SHOWS 45% REDUCTION IN RISK OF DEATH IN CHINA</p><p>   * ZAI LAB LTD: SAFETY PROFILE OF TIVDAK AMONG CHINA SUBPOPULATION WAS MANAGEABLE AND CONSISTENT WITH THAT OBSERVED IN GLOBAL POPULATIO</p><p>   * ZAI LAB LTD - MEDIAN OS FOR TIVDAK NOT REACHED VERSUS CHEMOTHERAPY 10.7 MONTHS</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>BRIEF-Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-15 21:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Jan 15 (Reuters) - Zai Lab Ltd   :</p><p>   * ZAI LAB ANNOUNCES POSITIVE TOPLINE RESULTS FOR TIVDAK IN THE CHINA SUBPOPULATION OF THE GLOBAL PHASE 3 INNOVATV 301 TRIAL IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER</p><p>   * ZAI LAB LTD - TO SUBMIT NDA FOR TIVDAK TO NMPA IN Q1 2025</p><p>   * ZAI LAB LTD - TIVDAK IMPROVES OS, PFS, AND ORR IN CHINA SUBPOPULATION</p><p>   * ZAI LAB LTD - TIVDAK SHOWS 45% REDUCTION IN RISK OF DEATH IN CHINA</p><p>   * ZAI LAB LTD: SAFETY PROFILE OF TIVDAK AMONG CHINA SUBPOPULATION WAS MANAGEABLE AND CONSISTENT WITH THAT OBSERVED IN GLOBAL POPULATIO</p><p>   * ZAI LAB LTD - MEDIAN OS FOR TIVDAK NOT REACHED VERSUS CHEMOTHERAPY 10.7 MONTHS</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2503431786","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503431786","pubTimestamp":1736946455,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 15  - Zai Lab Ltd   :   * ZAI LAB ANNOUNCES POSITIVE TOPLINE RESULTS FOR TIVDAK IN THE CHINA SUBPOPULATION OF THE GLOBAL PHASE 3 INNOVATV 301 TRIAL IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER   * ZAI LAB LTD - TO SUBMIT NDA FOR TIVDAK TO NMPA IN Q1 2025   * ZAI LAB LTD - TIVDAK IMPROVES OS, PFS, AND ORR IN CHINA SUBPOPULATION   * ZAI LAB LTD - TIVDAK SHOWS 45% REDUCTION IN RISK OF DEATH IN CHINA   * ZAI LAB LTD: SAFETY PROFILE OF TIVDAK AMONG CHINA SUBPOPULATION WAS MANAGEABLE AND CONSISTENT WITH THAT OBSERVED IN GLOBAL POPULATIO   * ZAI LAB LTD - MEDIAN OS FOR TIVDAK NOT REACHED VERSUS CHEMOTHERAPY 10.7 MONTHSSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1588":"回港中概股","09688":"再鼎医药","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1574":"生物医药B类股"},"translate_title":"BRIEF-再鼎医药宣布TIVDAK在复发或转移性宫颈癌患者全球3期innovaTV 301试验中国亚群中的积极顶线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":0.9},"content_text":"Jan 15 (Reuters) - Zai Lab Ltd   :   * ZAI LAB ANNOUNCES POSITIVE TOPLINE RESULTS FOR TIVDAK IN THE CHINA SUBPOPULATION OF THE GLOBAL PHASE 3 INNOVATV 301 TRIAL IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER   * ZAI LAB LTD - TO SUBMIT NDA FOR TIVDAK TO NMPA IN Q1 2025   * ZAI LAB LTD - TIVDAK IMPROVES OS, PFS, AND ORR IN CHINA SUBPOPULATION   * ZAI LAB LTD - TIVDAK SHOWS 45% REDUCTION IN RISK OF DEATH IN CHINA   * ZAI LAB LTD: SAFETY PROFILE OF TIVDAK AMONG CHINA SUBPOPULATION WAS MANAGEABLE AND CONSISTENT WITH THAT OBSERVED IN GLOBAL POPULATIO   * ZAI LAB LTD - MEDIAN OS FOR TIVDAK NOT REACHED VERSUS CHEMOTHERAPY 10.7 MONTHSSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1}}}